Evidence map›Paper›PMID 41293678›Full record

ArticleBiomedical optics express2025

Optical express-biopsy of gliomas using macroscopic fluorescence lifetime imaging.

Marina V Shirmanova, Daria A Sachkova, Ilya D Shchechkin, Elena B Kiseleva, Anastasia D Komarova, Ludmila S Kuhnina, Artem S Grishin, Evgenia L Bederina, Evgenia V Pyanova, Elizaveta E Ponomareva and 4 more

Abstract read
In one paragraph

Article in Biomedical optics express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marina V ShirmanovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Daria A SachkovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Ilya D ShchechkinInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.ORCID https://orcid.org/0009-0009-6071-8210
Elena B KiselevaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.ORCID https://orcid.org/0000-0003-4769-417X
Anastasia D KomarovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.ORCID https://orcid.org/0000-0001-7709-5755
Ludmila S KuhninaDepartment of Neurosurgery, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Artem S GrishinDepartment of Pathology, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Evgenia L BederinaDepartment of Pathology, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Evgenia V PyanovaDepartment of Pathology, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Elizaveta E PonomarevaInstitute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Igor A MedyanikDepartment of Neurosurgery, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Leonid Y KravetsDepartment of Neurosurgery, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Vladislav I ShcheslavskiyInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Konstantin S YashinDepartment of Neurosurgery, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In glioma surgery, the quality of tumor resection largely determines patient prognosis. Accurate intraoperative discrimination of glial tumors from normal brain tissue and delineation of tumor margins is a major challenge. Given the inherent biochemical differences between tumor and normal tissue, imaging techniques based on cellular autofluorescence represent a promising approach to address this challenge. The aim of this study was to evaluate the ability of macroscopic fluorescence lifetime imaging, macro-FLIM, to discriminate between different classes of glioma (glioblastoma, astrocytoma, oligodendroglioma) and normal brain tissue and to identify glioma cells in the peritumoral region. The study was performed on 110 freshly excised tissue samples from 53 patients. Macro-FLIM images were acquired in the NAD(P)H spectral channel (ex. 375 nm, em. 435-485 nm) using a confocal laser macroscanner. In human performance, the sensitivity of macro-FLIM in discriminating glioblastoma from normal tissue was 92.3% (AUC 0.905), astrocytoma and oligodendroglioma - 62.5% (AUC 0.796 and 0.687). To automatically classify the macro-FLIM images, the Random Forests machine learning algorithm was developed, which reliably discriminated glioblastoma from all normal (82.4% sensitivity, AUC 0.86), astrocytoma from white matter (80.3% sensitivity, AUC 0.857), and oligodendroglioma from gray matter (89.2% sensitivity, AUC 0.875). In addition, the classification model demonstrated the ability to detect areas of tumor infiltration within the peritumoral white matter. The current results demonstrate the potential of NAD(P)H-based macro-FLIM combined with machine learning as a surgical guidance tool to improve glioma resection.

Identifiers

PMID41293678
PMCPMC12643007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.